Abstract: The method of adjusting the saturation concentration of a drug in a transdermal composition for application to the dermis, which comprises mixing polymers having differing solubility parameters, so as to modulate the delivery of the drug. This results in the ability to achieve a predetermined permeation rate of the drug into and through the dermis. In one embodiment, a dermal composition of the present invention comprises a drug, an acrylate polymer, and a polysiloxane. The dermal compositions can be produced by a variety of methods known in the preparation of drug-containing adhesive preparations, including the mixing of the polymers, drug, and additional ingredients in solution, followed by removal of the processing solvents. The method and composition of this invention permit selectable loading of the drug into the dermal formulation and adjustment of the delivery rate of the drug from the composition through the dermis, while maintaining acceptable shear, tack, and peel adhesive properties.

Abstract: Compositions containing at least one alpha hydroxyacid, salicylic acid, and at least one digestive enzyme derived from fruit are disclosed for cosmetic uses in the treatment of various skin conditions such as lack of adequate skin firmness, wrinkles, and dry skin. Various formulations of the compositions including gels, creams, lotions and ointments are disclosed for topical use. The alpha hydroxyacids include glycolic acid, lactic acid and citric acid. The digestive enzymes include bromelain and papain.

Abstract: The present invention relates to a process for the preparation of compounds of the formula I ##STR1## where X is CH.dbd.CH, N.dbd.CH, CH.dbd.N or S,R.sup.1 and R.sup.2 independently of one another are H, halogen, alkyl, alkoxy, alkylthio, haloalkyl, haloalkoxy, haloalkylthio or the bivalent methylenedioxy group,R.sup.3 is a radical of the formulae (A), (B) or (C) ##STR2## where R.sup.4 and R.sup.5 independently of one another are H, halogen, alkyl, alkoxy or a radical of the formula (D) ##STR3## in which R.sup.6 is H or halogen andY is CH.sub.2, O or S, andm, n, o, p and q are 0, 1, or 2, which comprises reacting a compound of the formula IIH.sub.2 C.dbd.CH--CH.sub.2 --R.sup.3 (II)where R.sup.3 is as defined in formula I, with dichloromethylsilane in the presence of a catalyst suitable for hydrosilylation reactions, and reacting the resulting intermediate of the formula III ##STR4## where R.sup.

Abstract: The present invention relates to racemic or optically active cis octahydro-indolo [2,3-a] quinolizine diester derivatives.

Abstract: The invention concerns intermediates having the formula ##STR1## wherein R is 2-propylpentyl optionally with one, two or three internal unsaturated bonds, or 2-substituted-2-propylpentyl optionally with one or two internal unsaturated bonds wherein the 2-substituent is a leaving group.

Abstract: Partially fluorinated tetracarboxylic acid and the dianhydride thereof, a process for their preparation and their useA compound of the formula ##STR1## and the dianhydride thereof are prepared by air oxidation in the presence of a catalyst mixture composed of at least 2 heavy metal salts and also bromine in an acid organic medium. The compounds can be employed for the preparation of partially fluorinated polycondensates, such as polyimides, polycarboxamides, esters of polyamidecarboxylic acids, polyamides and imide-oligomers.

Abstract: There are disclosed compounds of the formula ##STR1## wherein a is alkyl 3-19 carbon atoms, diloweralkyl allyl, diahaloallyl, diphenylallyl, lower alkynyl, ##STR2## W is --CR.sub.2 O--, --CH.dbd.CH-- or --CH.dbd.CHCH.sub.2 O-- X is N or CR;Z is ##STR3## R is hydrogen or lower alkyl; Y is ##STR4## R.sup.1 is hydrogen, lower alkyl or phenyl; R.sup.2 is hydrogen or lower alkyl; orR.sup.1 and R.sup.2 taken together form a benzene ring, optionally substituted by halo;R.sup.3 is --OR, ##STR5## -- NHSO.sub.2 R.sup.4 ; R.sup.4 is phenyl or loweralkyl substituted phenyl;R.sup.5 is halo;and the pharmaceutically acceptable salts thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as alelrgic rhinitis, allergic bronchial asthma and the like, in psoriasis, ulcerative colitis, rheumatoid arthritis as well as in other immediate hypersensitivity reactions.

Abstract: Crude organic solutions of N,N-dialkylcarbamoylmethylphosphine oxide compounds can be purified by treatment with a first row transition metal salt to form a complex which can be treated to regenerate a purified solution of the compound. The first row transition metal can be selected from the monobasic acid salts of zinc, for example.

Abstract: Phosphorus compounds having at least one chlorine, bromine or iodine bonded directly to phosphorus are transhalogenated with fluorine by reaction with anhydrous hydrogen fluoride in an inert solvent, e.g., xylene, methylene chloride, in a manner such that said anhydrous hydrogen fluoride is added to said phosphorus compound at a rate such that said anhydrous hydrogen fluoride reacts with said phosphorus compound without the accumulation of an amount of unreacted anhydrous hydrogen fluoride which is sufficient to cause substantial decomposition of the desired fluorophosphorus product.

Abstract: Compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof, R.sup.1 is hydrogen, alkyl or aryl unsubstituted or substituted by one or two halo moieties, R.sup.3 is hydrogen or alkyl, A is N, W is O or NR.sup.3 wherein R.sup.3 is hydrogen, alkyl, acyl, haloacyl, 2alkoxycarbonyl or (5-methyl-2-oxo-1,3-dioxolen-4-yl) methyl are useful for treating bacterial infections in humans and animals.